Status:
COMPLETED
Response of Haemodialysis Patients to BNT162b2 mRNA Cov-19 Vaccine
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
COVID-19 Vaccines
Hemodialysis Complication
Eligibility:
All Genders
18-130 years
Brief Summary
Vaccination against SARS-Cov2 is a necessity for haemodialysis patients because difficulties to maintain a self-isolation (leading to a higher contamination than general population) and an increase of...
Eligibility Criteria
Inclusion
- Medical prescription of BTN162b2 mRNA Cov-19 vaccine
- Treatment by chronic (\>1 month) haemodialysis
Exclusion
- Non-recommended vaccination scheme
- Refusal to consent
Key Trial Info
Start Date :
May 10 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 15 2022
Estimated Enrollment :
99 Patients enrolled
Trial Details
Trial ID
NCT04881396
Start Date
May 10 2021
End Date
February 15 2022
Last Update
May 10 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Nephrology, Hopital Edouard Herriot
Lyon, France, 69003
2
Department of Nephrology, Centre Hospitalier Lyon Sud
Pierre-Bénite, France, 69495